<DOC>
	<DOCNO>NCT02148913</DOCNO>
	<brief_summary>This phase I clinical trial . Patients diagnosis multiple myeloma undergo autologous transplantation receive preparative regimen melphalan , bendamustine , carfilzomib . We hypothesize addition carfilzomib condition regimen melphalan bendamustine set autologous transplantation multiple myeloma feasible safe .</brief_summary>
	<brief_title>Phase I : Melphalan , Bendamustine Carfilzomib Autologous Transplant Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Diagnosis multiple myeloma At least 2 x 106 CD34+ cells/kg collect patient cryopreserved ASCT Greater 18 year Karnofsky score great 70 % No evidence progressive bacterial , viral , fungal infection Absolute neutrophil count 1000 Platelet count 50,000 Hemoglobin 8 g/dL Creatinine clearance great 50 mL/min Total bilirubin , ALT , AST le 2 x upper limit normal Alkaline phosphatase less equal 250 IU/L Left Ventricular Ejection Fraction ( LVEF ) great equal 45 % Adjusted Carbon Monoxide Diffusing Capacity ( DLCO ) great equal 60 % Negative HIV serology Recovered toxicity previous chemotherapy ( excludes grade 1 neurotoxicity hematological toxicity ) Patients pretransplant disease status consistent good partial response ( VGPR ) , partial response ( PR ) , stable disease ( SD ) , progressive disease ( PD ) , relapse complete remission ( CR ) . Patients refractory carfilzomib . Refractory define disease progression carfilzomib therapy receive least two cycle treatment . Patients complete response ( CR ) ( include near CR stringent CR ) conventional induction therapy proceed transplantation . Pregnant nursing female woman reproductive capability unwilling use effective contraception . A woman reproductive capability one undergone hysterectomy ( removal womb ) , ovaries remove , postmenopausal ( stop menstrual period ) 24 month row . Male subject refuse practice effective barrier contraception entire study treatment period minimum 30 day last dose study drug , completely abstain heterosexual intercourse . This must do even surgically sterilize ( ie , postvasectomy ) . Patient Grade 2 peripheral neuropathy Inability provide inform consent Patient myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , ECG abnormality screen must document investigator medically relevant . Known allergy component investigational treatment regimen require ancillary treatment . Serious medical psychiatric illness likely interfere participation clinical study . Diagnosed treat another malignancy within 3 year enrollment ( exception nonmelanoma skin cancer ) . Participation clinical trial investigational agent include trial , within 14 day start trial throughout duration trial . Prisoner</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>